US 12,005,207 B2
Chemical ablation and method of treatment for various diseases
Lixiao Wang, Henderson, NV (US); John J. Chen, Plymouth, MN (US); and Yongxing Zhang, Irvine, CA (US)
Assigned to Neurotronic, Inc., Plymouth, MN (US)
Filed by Neurotronic, Inc., Plymouth, MN (US)
Filed on Aug. 6, 2020, as Appl. No. 16/986,717.
Application 16/986,717 is a continuation of application No. 16/563,213, filed on Sep. 6, 2019, granted, now 11,648,378.
Application 16/563,213 is a continuation of application No. 16/156,163, filed on Oct. 10, 2018, granted, now 10,758,713.
Application 16/156,163 is a continuation of application No. 15/521,973, granted, now 10,286,191, previously published as PCT/US2015/058296, filed on Oct. 30, 2015.
Claims priority of provisional application 62/124,868, filed on Jan. 5, 2015.
Claims priority of provisional application 62/122,818, filed on Oct. 30, 2014.
Prior Publication US 2020/0360671 A1, Nov. 19, 2020
Int. Cl. A61M 25/10 (2013.01); A61B 18/06 (2006.01); A61K 31/045 (2006.01); A61M 5/00 (2006.01); A61M 5/142 (2006.01); A61M 5/172 (2006.01); A61M 29/02 (2006.01); A61B 18/00 (2006.01)
CPC A61M 25/1002 (2013.01) [A61B 18/06 (2013.01); A61K 31/045 (2013.01); A61M 5/007 (2013.01); A61M 5/142 (2013.01); A61M 5/172 (2013.01); A61M 25/1011 (2013.01); A61M 29/02 (2013.01); A61B 2018/00577 (2013.01); A61M 2025/105 (2013.01); A61M 2025/1052 (2013.01); A61M 2202/02 (2013.01)] 8 Claims
OG exemplary drawing
 
1. A method for treating diabetes and obesity, the method comprising:
inserting a first delivery catheter that is a needle catheter or a needle-based catheter into a first treatment site in a common hepatic artery;
infusing a chemical formulation from a formulation infusion lumen of the first delivery catheter to a tissue of the body lumen at the first treatment site, wherein the chemical formulation infused is effective to injure and/or damage the tissue at the first treatment site;
withdrawing the first delivery catheter from the first treatment site;
inserting a second delivery catheter that is the same or different as the first delivery catheter and that is a needle catheter or a needle-based catheter into a second treatment site in the common hepatic artery, wherein the second treatment site is a different treatment site than the first treatment site;
infusing a chemical formulation from a formulation infusion lumen of the second delivery catheter to a tissue of the body lumen at the second treatment site, wherein the chemical formulation infused is effective to injure and/or damage the tissue at the second treatment site; and
withdrawing the second delivery catheter from the second treatment site;
wherein the injury and/or damage to the tissue at the first treatment site and to the tissue at the second treatment site is effective to have a benefit of relieving symptoms comprising reduction of HbA1c (A1c), glucose level, and body weight; and
wherein the first and/or second delivery catheter comprises a balloon around a circumference of a shaft and the formulation infusion lumen in the shaft that passes through a region of the shaft that comprises the balloon thereon.